Author:
Rolsma Jordan L.,Darch William,Higgins Nicholas C.,Morgan Joshua T.
Abstract
AbstractHuman adipose-derived stem cell (ASC) grafts have emerged as a powerful tool in regenerative medicine. However, ASC therapeutic potential is hindered by stressors throughout their use. Here we demonstrate the transgenic expression of the tardigrade-derived mitochondrial abundant heat soluble (MAHS) protein for improved ASC resistance to metabolic, mitochondrial, and injection shear stress. In vitro, MAHS-expressing ASCs demonstrate up to 61% increased cell survival following 72 h of incubation in phosphate buffered saline containing 20% media. Following up to 3.5% DMSO exposure for up to 72 h, a 14–49% increase in MAHS-expressing ASC survival was observed. Further, MAHS expression in ASCs is associated with up to 39% improved cell viability following injection through clinically relevant 27-, 32-, and 34-gauge needles. Our results reveal that MAHS expression in ASCs supports survival in response to a variety of common stressors associated with regenerative therapies, thereby motivating further investigation into MAHS as an agent for stem cell stress resistance. However, differentiation capacity in MAHS-expressing ASCs appears to be skewed in favor of osteogenesis over adipogenesis. Specifically, activity of the early bone formation marker alkaline phosphatase is increased by 74% in MAHS-expressing ASCs following 14 days in osteogenic media. Conversely, positive area of the neutral lipid droplet marker BODIPY is decreased by up to 10% in MAHS-transgenic ASCs following 14 days in adipogenic media. Interestingly, media supplementation with up to 40 mM glucose is sufficient to restore adipogenic differentiation within 14 days, prompting further analysis of mechanisms underlying interference between MAHS and differentiation processes.
Funder
California Institute for Regenerative Medicine
California Space Grant Consortium
Directorate for Engineering
American Heart Association
Publisher
Springer Science and Business Media LLC
Reference108 articles.
1. Aly, R. M. Current state of stem cell-based therapies: An overview. Stem Cell Investig. 7, 8–8 (2020).
2. Stem Cell Therapy Market (By Product: Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs), Very Small Embryonic Like Stem Cells; By Therapy Type; By Application; By Technology; By End User)—Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022–2030. https://www.precedenceresearch.com/stem-cell-therapy-market. Accessed 17 Aug 2023.
3. Si, Z. et al. Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies. Biomed. Pharmacother. 114, 108765 (2019).
4. Tsuji, W. Adipose-derived stem cells: Implications in tissue regeneration. World J. Stem Cells 6, 312 (2014).
5. Yano, F. et al. Effects of conditioned medium obtained from human adipose-derived stem cells on skin inflammation. Regen. Ther. 20, 72–77 (2022).